Search Results for: lung cancer

The test addresses high-volume, high-value need with broad coverage of validated mutations.

The coverage decision means that more than 49 million eligible Medicare enrollees in the United States will now be able to benefit from VeriStrat being a covered diagnostic test, according to specific lung cancer indications outlined by Novitas.

Robust discussion follows disclosure of an attempt to foil cancer.

This is the first FDA-approved companion diagnostic that detects epidermal growth factor receptor gene mutations, which are present in approximately 10% of non-small cell lung cancers.